onecut2 overexpression plasmid Search Results


onecut2 overexpression plasmid  (OriGene)
92
OriGene onecut2 overexpression plasmid
(A) MDA231, MCF-7, and BT474 cells were transfected with siRNA against <t>ONECUT2</t> (GeneSolution/GS including equal mixture of 4 preselected siRNAs, or individual siRNA #1 and #2), or a control siRNA, or with PBS. After 48 h, cells were collected for sphere formation assay. (B) ALDEFLUOR assay of MDA231 cells transfected with siRNA as indicated for 72 h. (C) RT-qPCR-determined RNA levels of indicated genes in various BC cells at 48 h following transfection with indicated siRNA. (D) Western blots showing the expression levels of indicated proteins in BC cells at 48 h following transfection of ONECUT2 siRNA-GS or control siRNA. (E) MDA231 cells were transfected with indicated siRNA and seeded at an equal number on day 0. DTX (10 nM) or DOXO (500 nM) was added on day 1, and replenished every 24 h. On day 3, cell viability (left) and cell number (right) were determined by MTS assay and cell counting, respectively, and compared to the PBS treatment group. (F) RT-qPCR of indicated genes in MDA231 cells at 72 h after transfection with indicated siRNA. *P<0.05, **P<0.01, ***P<0.001 compared to control siRNA or as indicated. Numbers below Western images indicate quantification after normalization to GAPDH with the first lane set as 1.
Onecut2 Overexpression Plasmid, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/onecut2+overexpression+plasmid/pmc08972808-54-1-8?v=OriGene
Average 92 stars, based on 1 article reviews
onecut2 overexpression plasmid - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
onecut2  (Genechem)
86
Genechem onecut2
CircRERE(4-5) upregulates <t>ONECUT2</t> by sponging miR-571. (A) qRT–PCR demonstrating the enrichment of circRNAs in a representative anti-AGO2 RIP assay conducted in GC cells. (B) Venn diagram illustrating the overlap of candidate miRNAs predicted to interact with circRERE(4-5) by two open-access databases. (C) qRT–PCR showing the enrichment of miRNAs following circRERE(4-5) pull-down in lysates of GC cells. (D) Venn diagram depicting the intersection of candidate mRNAs targeted by miR-571 as predicted by three open-access databases. (E) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)). (F) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells transfected with control inhibitors or miR-571 inhibitors. (G) Western blotting revealing ONECUT2 protein levels in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)), with GAPDH serving as a loading control. (H) Western blotting showing ONECUT2 protein levels in GC cells transfected with control inhibitors or miR-571 inhibitors. (I) qRT–PCR analysis of ONECUT2 mRNA expression in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (J) Representative western blot of ONECUT2 in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (K) Sequence alignment analysis highlighting the binding sites of circRERE(4-5) and ONECUT2 3’ UTR on miR-571. Data are presented as the mean ± SD. P -values were calculated using a two-tailed unpaired Student’s t -test (E, F, I) ; ** P < 0.01, *** P < 0.001. See also <xref ref-type=Supplementary Figure 4 . " width="250" height="auto" />
Onecut2, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/onecut2+overexpression+plasmid/pmc13002853-63-6-10?v=Genechem
Average 86 stars, based on 1 article reviews
onecut2 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
cut homeobox 2  (OriGene)
93
OriGene cut homeobox 2
CircRERE(4-5) upregulates <t>ONECUT2</t> by sponging miR-571. (A) qRT–PCR demonstrating the enrichment of circRNAs in a representative anti-AGO2 RIP assay conducted in GC cells. (B) Venn diagram illustrating the overlap of candidate miRNAs predicted to interact with circRERE(4-5) by two open-access databases. (C) qRT–PCR showing the enrichment of miRNAs following circRERE(4-5) pull-down in lysates of GC cells. (D) Venn diagram depicting the intersection of candidate mRNAs targeted by miR-571 as predicted by three open-access databases. (E) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)). (F) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells transfected with control inhibitors or miR-571 inhibitors. (G) Western blotting revealing ONECUT2 protein levels in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)), with GAPDH serving as a loading control. (H) Western blotting showing ONECUT2 protein levels in GC cells transfected with control inhibitors or miR-571 inhibitors. (I) qRT–PCR analysis of ONECUT2 mRNA expression in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (J) Representative western blot of ONECUT2 in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (K) Sequence alignment analysis highlighting the binding sites of circRERE(4-5) and ONECUT2 3’ UTR on miR-571. Data are presented as the mean ± SD. P -values were calculated using a two-tailed unpaired Student’s t -test (E, F, I) ; ** P < 0.01, *** P < 0.001. See also <xref ref-type=Supplementary Figure 4 . " width="250" height="auto" />
Cut Homeobox 2, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/onecut2+overexpression+plasmid/pmc11850477-48-15-8?v=OriGene
Average 93 stars, based on 1 article reviews
cut homeobox 2 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
lentiviral vectors of overexpression onecut2  (Ribobio co)
90
Ribobio co lentiviral vectors of overexpression onecut2
CircRERE(4-5) upregulates <t>ONECUT2</t> by sponging miR-571. (A) qRT–PCR demonstrating the enrichment of circRNAs in a representative anti-AGO2 RIP assay conducted in GC cells. (B) Venn diagram illustrating the overlap of candidate miRNAs predicted to interact with circRERE(4-5) by two open-access databases. (C) qRT–PCR showing the enrichment of miRNAs following circRERE(4-5) pull-down in lysates of GC cells. (D) Venn diagram depicting the intersection of candidate mRNAs targeted by miR-571 as predicted by three open-access databases. (E) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)). (F) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells transfected with control inhibitors or miR-571 inhibitors. (G) Western blotting revealing ONECUT2 protein levels in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)), with GAPDH serving as a loading control. (H) Western blotting showing ONECUT2 protein levels in GC cells transfected with control inhibitors or miR-571 inhibitors. (I) qRT–PCR analysis of ONECUT2 mRNA expression in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (J) Representative western blot of ONECUT2 in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (K) Sequence alignment analysis highlighting the binding sites of circRERE(4-5) and ONECUT2 3’ UTR on miR-571. Data are presented as the mean ± SD. P -values were calculated using a two-tailed unpaired Student’s t -test (E, F, I) ; ** P < 0.01, *** P < 0.001. See also <xref ref-type=Supplementary Figure 4 . " width="250" height="auto" />
Lentiviral Vectors Of Overexpression Onecut2, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/onecut2+overexpression+plasmid/pm40286271-194-4-15?v=Ribobio+co
Average 90 stars, based on 1 article reviews
lentiviral vectors of overexpression onecut2 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


(A) MDA231, MCF-7, and BT474 cells were transfected with siRNA against ONECUT2 (GeneSolution/GS including equal mixture of 4 preselected siRNAs, or individual siRNA #1 and #2), or a control siRNA, or with PBS. After 48 h, cells were collected for sphere formation assay. (B) ALDEFLUOR assay of MDA231 cells transfected with siRNA as indicated for 72 h. (C) RT-qPCR-determined RNA levels of indicated genes in various BC cells at 48 h following transfection with indicated siRNA. (D) Western blots showing the expression levels of indicated proteins in BC cells at 48 h following transfection of ONECUT2 siRNA-GS or control siRNA. (E) MDA231 cells were transfected with indicated siRNA and seeded at an equal number on day 0. DTX (10 nM) or DOXO (500 nM) was added on day 1, and replenished every 24 h. On day 3, cell viability (left) and cell number (right) were determined by MTS assay and cell counting, respectively, and compared to the PBS treatment group. (F) RT-qPCR of indicated genes in MDA231 cells at 72 h after transfection with indicated siRNA. *P<0.05, **P<0.01, ***P<0.001 compared to control siRNA or as indicated. Numbers below Western images indicate quantification after normalization to GAPDH with the first lane set as 1.

Journal: Cancer research

Article Title: Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2

doi: 10.1158/0008-5472.CAN-18-4055

Figure Lengend Snippet: (A) MDA231, MCF-7, and BT474 cells were transfected with siRNA against ONECUT2 (GeneSolution/GS including equal mixture of 4 preselected siRNAs, or individual siRNA #1 and #2), or a control siRNA, or with PBS. After 48 h, cells were collected for sphere formation assay. (B) ALDEFLUOR assay of MDA231 cells transfected with siRNA as indicated for 72 h. (C) RT-qPCR-determined RNA levels of indicated genes in various BC cells at 48 h following transfection with indicated siRNA. (D) Western blots showing the expression levels of indicated proteins in BC cells at 48 h following transfection of ONECUT2 siRNA-GS or control siRNA. (E) MDA231 cells were transfected with indicated siRNA and seeded at an equal number on day 0. DTX (10 nM) or DOXO (500 nM) was added on day 1, and replenished every 24 h. On day 3, cell viability (left) and cell number (right) were determined by MTS assay and cell counting, respectively, and compared to the PBS treatment group. (F) RT-qPCR of indicated genes in MDA231 cells at 72 h after transfection with indicated siRNA. *P<0.05, **P<0.01, ***P<0.001 compared to control siRNA or as indicated. Numbers below Western images indicate quantification after normalization to GAPDH with the first lane set as 1.

Article Snippet: The ONECUT2 overexpression plasmid (#RC211951) was purchased from OriGene (Rockville, MD); stable transfection of MDA231 cells was achieved by G418 selection to generate the MDA231/ONECUT2 cells.

Techniques: Transfection, Control, Tube Formation Assay, Quantitative RT-PCR, Western Blot, Expressing, MTS Assay, Cell Counting

(A,B) MDA231 cells stably expressing a mammalian expression plasmid of human ONECUT2 cDNA or the empty vector were exposed to PBS or EVs from PBS/DTX/DOXO-treated MDA231 cells for 48 h before being analyzed by sphere formation assay (A) and Western blots (B). (C) RT-qPCR-determined RNA levels of indicated genes in MDA231 cells stably expressing ONECUT2 or vector. (D) MDA231, MCF-7, and BT474 cells transfected with the ONECUT2 expression plasmid or empty vector were analyzed by Western blots. (E) MDA231 cells stably expressing ONECUT2 or vector were seeded at an equal number on day 0. DTX (10 nM) or DOXO (500 nM) was added after 6 h, and replenished every 24 h. Cell viability (left) was measured by MTS assay every 24 h and cell number (right) was determined by cell counting on day 3. Data were normalized to the PBS control group. (F) RT-qPCR of indicated genes in MDA231 cells stably expressing ONECUT2 or vector. *P<0.05, **P<0.01, ***P<0.001. Numbers below Western images indicate quantification after normalization to GAPDH with the first lane set as 1.

Journal: Cancer research

Article Title: Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2

doi: 10.1158/0008-5472.CAN-18-4055

Figure Lengend Snippet: (A,B) MDA231 cells stably expressing a mammalian expression plasmid of human ONECUT2 cDNA or the empty vector were exposed to PBS or EVs from PBS/DTX/DOXO-treated MDA231 cells for 48 h before being analyzed by sphere formation assay (A) and Western blots (B). (C) RT-qPCR-determined RNA levels of indicated genes in MDA231 cells stably expressing ONECUT2 or vector. (D) MDA231, MCF-7, and BT474 cells transfected with the ONECUT2 expression plasmid or empty vector were analyzed by Western blots. (E) MDA231 cells stably expressing ONECUT2 or vector were seeded at an equal number on day 0. DTX (10 nM) or DOXO (500 nM) was added after 6 h, and replenished every 24 h. Cell viability (left) was measured by MTS assay every 24 h and cell number (right) was determined by cell counting on day 3. Data were normalized to the PBS control group. (F) RT-qPCR of indicated genes in MDA231 cells stably expressing ONECUT2 or vector. *P<0.05, **P<0.01, ***P<0.001. Numbers below Western images indicate quantification after normalization to GAPDH with the first lane set as 1.

Article Snippet: The ONECUT2 overexpression plasmid (#RC211951) was purchased from OriGene (Rockville, MD); stable transfection of MDA231 cells was achieved by G418 selection to generate the MDA231/ONECUT2 cells.

Techniques: Stable Transfection, Expressing, Plasmid Preparation, Tube Formation Assay, Western Blot, Quantitative RT-PCR, Transfection, MTS Assay, Cell Counting, Control

(A) A schematic representative showing putative binding sites of miR-9–5p, miR-203a-3p, and miR-195–5p in the 3’UTR of human ONECUT2 and the regions cloned into the luciferase reporter plasmid constructs. (B) MDA231 cells were transfected with psiCHECK2 reporter plasmids containing indicated ONECUT2 3’UTR region or with the psiCHECK2 vector (2 µg DNA per 2×105 cells). After 12 h, transfected cells were exposed to PBS or EVs from PBS/DTX (4 nM)/DOXO (125 nM)-treated MDA231 cells for 48 h before luciferase activities were measured. Ratio between Renilla luciferase and firefly luciferase activities (Rluc/Fluc) is shown. (C) MDA231 cells were co-transfected with indicated psiCHECK2 reporter plasmids (2 µg DNA per 2×105 cells) and miRNA mimics (individually or with a 1:1:1 mixture of miR-9–5p, miR-203a-3p, and miR-195–5p mimics for a total of 25 pmol). Luciferase activities were analyzed at 48 h. *P<0.05, **P<0.01, ***P<0.001.

Journal: Cancer research

Article Title: Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2

doi: 10.1158/0008-5472.CAN-18-4055

Figure Lengend Snippet: (A) A schematic representative showing putative binding sites of miR-9–5p, miR-203a-3p, and miR-195–5p in the 3’UTR of human ONECUT2 and the regions cloned into the luciferase reporter plasmid constructs. (B) MDA231 cells were transfected with psiCHECK2 reporter plasmids containing indicated ONECUT2 3’UTR region or with the psiCHECK2 vector (2 µg DNA per 2×105 cells). After 12 h, transfected cells were exposed to PBS or EVs from PBS/DTX (4 nM)/DOXO (125 nM)-treated MDA231 cells for 48 h before luciferase activities were measured. Ratio between Renilla luciferase and firefly luciferase activities (Rluc/Fluc) is shown. (C) MDA231 cells were co-transfected with indicated psiCHECK2 reporter plasmids (2 µg DNA per 2×105 cells) and miRNA mimics (individually or with a 1:1:1 mixture of miR-9–5p, miR-203a-3p, and miR-195–5p mimics for a total of 25 pmol). Luciferase activities were analyzed at 48 h. *P<0.05, **P<0.01, ***P<0.001.

Article Snippet: The ONECUT2 overexpression plasmid (#RC211951) was purchased from OriGene (Rockville, MD); stable transfection of MDA231 cells was achieved by G418 selection to generate the MDA231/ONECUT2 cells.

Techniques: Binding Assay, Clone Assay, Luciferase, Plasmid Preparation, Construct, Transfection

(A) Left: Western blots showing modified expression of Rab27a and Onecut2 in indicated cell lines. Right: nanoparticle tracking analysis of EVs from an equal number of producing cells showing reduced EV secretion by MDA231/Rab27aKD cells. (B-E) Xenograft tumors were established in NSG mice by injecting 2×105 of indicated cells into the #4 mammary fat pad. When tumor size reached ~300 mm3, mice were treated weekly with DTX (15 mg/kg) for 3 weeks. (B) Tumor onset and volume. The time of DTX treatments were indicated by arrows. (C) Western blots of indicated proteins using tumors collected before and after DTX treatment. Numbers below Western images indicate quantification after normalization to GAPDH with the first lane set as 1. (D) RT-qPCR analysis of indicated genes using tumors collected before and after DTX treatment. (E) EVs were prepared from the sera of indicated mice before and after the 3-week DTX treatment. Levels of miRNAs were determined by RT-qPCR using a cel-miR-39–3p spike-in control for normalization. (F) Twelve pairs of pre- and post-NT human breast tumors were analyzed by IHC to determine the ONECUT2 expression levels in tumor cells. Wilcoxon test was performed. *P<0.05, **P<0.01, ***P<0.001.

Journal: Cancer research

Article Title: Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2

doi: 10.1158/0008-5472.CAN-18-4055

Figure Lengend Snippet: (A) Left: Western blots showing modified expression of Rab27a and Onecut2 in indicated cell lines. Right: nanoparticle tracking analysis of EVs from an equal number of producing cells showing reduced EV secretion by MDA231/Rab27aKD cells. (B-E) Xenograft tumors were established in NSG mice by injecting 2×105 of indicated cells into the #4 mammary fat pad. When tumor size reached ~300 mm3, mice were treated weekly with DTX (15 mg/kg) for 3 weeks. (B) Tumor onset and volume. The time of DTX treatments were indicated by arrows. (C) Western blots of indicated proteins using tumors collected before and after DTX treatment. Numbers below Western images indicate quantification after normalization to GAPDH with the first lane set as 1. (D) RT-qPCR analysis of indicated genes using tumors collected before and after DTX treatment. (E) EVs were prepared from the sera of indicated mice before and after the 3-week DTX treatment. Levels of miRNAs were determined by RT-qPCR using a cel-miR-39–3p spike-in control for normalization. (F) Twelve pairs of pre- and post-NT human breast tumors were analyzed by IHC to determine the ONECUT2 expression levels in tumor cells. Wilcoxon test was performed. *P<0.05, **P<0.01, ***P<0.001.

Article Snippet: The ONECUT2 overexpression plasmid (#RC211951) was purchased from OriGene (Rockville, MD); stable transfection of MDA231 cells was achieved by G418 selection to generate the MDA231/ONECUT2 cells.

Techniques: Western Blot, Modification, Expressing, Quantitative RT-PCR, Control

CircRERE(4-5) upregulates ONECUT2 by sponging miR-571. (A) qRT–PCR demonstrating the enrichment of circRNAs in a representative anti-AGO2 RIP assay conducted in GC cells. (B) Venn diagram illustrating the overlap of candidate miRNAs predicted to interact with circRERE(4-5) by two open-access databases. (C) qRT–PCR showing the enrichment of miRNAs following circRERE(4-5) pull-down in lysates of GC cells. (D) Venn diagram depicting the intersection of candidate mRNAs targeted by miR-571 as predicted by three open-access databases. (E) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)). (F) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells transfected with control inhibitors or miR-571 inhibitors. (G) Western blotting revealing ONECUT2 protein levels in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)), with GAPDH serving as a loading control. (H) Western blotting showing ONECUT2 protein levels in GC cells transfected with control inhibitors or miR-571 inhibitors. (I) qRT–PCR analysis of ONECUT2 mRNA expression in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (J) Representative western blot of ONECUT2 in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (K) Sequence alignment analysis highlighting the binding sites of circRERE(4-5) and ONECUT2 3’ UTR on miR-571. Data are presented as the mean ± SD. P -values were calculated using a two-tailed unpaired Student’s t -test (E, F, I) ; ** P < 0.01, *** P < 0.001. See also <xref ref-type=Supplementary Figure 4 . " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Silencing of circRERE(4-5) inhibits ONECUT2-mediated tumorigenesis and metastasis in gastric cancer

doi: 10.3389/fimmu.2026.1686702

Figure Lengend Snippet: CircRERE(4-5) upregulates ONECUT2 by sponging miR-571. (A) qRT–PCR demonstrating the enrichment of circRNAs in a representative anti-AGO2 RIP assay conducted in GC cells. (B) Venn diagram illustrating the overlap of candidate miRNAs predicted to interact with circRERE(4-5) by two open-access databases. (C) qRT–PCR showing the enrichment of miRNAs following circRERE(4-5) pull-down in lysates of GC cells. (D) Venn diagram depicting the intersection of candidate mRNAs targeted by miR-571 as predicted by three open-access databases. (E) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)). (F) qRT–PCR analysis of ONECUT2 mRNA expression in GC cells transfected with control inhibitors or miR-571 inhibitors. (G) Western blotting revealing ONECUT2 protein levels in GC cells under control conditions (sh-NC) or with circRERE(4-5) knockdown (sh-circRERE(4-5)), with GAPDH serving as a loading control. (H) Western blotting showing ONECUT2 protein levels in GC cells transfected with control inhibitors or miR-571 inhibitors. (I) qRT–PCR analysis of ONECUT2 mRNA expression in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (J) Representative western blot of ONECUT2 in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and miR-571 inhibitors. (K) Sequence alignment analysis highlighting the binding sites of circRERE(4-5) and ONECUT2 3’ UTR on miR-571. Data are presented as the mean ± SD. P -values were calculated using a two-tailed unpaired Student’s t -test (E, F, I) ; ** P < 0.01, *** P < 0.001. See also Supplementary Figure 4 .

Article Snippet: Additionally, the overexpression vectors (GV367) for ONECUT2 were obtained from GeneChem.

Techniques: Quantitative RT-PCR, Expressing, Control, Knockdown, Transfection, Western Blot, Cotransfection, Sequencing, Binding Assay, Two Tailed Test

CircRERE(4-5) promotes oncogenic activity through ONECUT2 in GC cells. (A) Representative western blot of ONECUT2 protein in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. (B, C) Plate colony formation assay evaluating colony formation in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. (D) CCK-8 assay depicting the proliferation of AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. (E, F) Transwell migration assay illustrating the migration of AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. Scale bar, 100 µm. (G, H) Wound healing assay demonstrating the migration of AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. Scale bar, 200 µm. Data are presented as the mean ± SD. P- values were calculated using a two-tailed unpaired Student’s t -test (C, F, H) or two-way ANOVA (D) ; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. See also <xref ref-type=Supplementary Figure 5 . " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Silencing of circRERE(4-5) inhibits ONECUT2-mediated tumorigenesis and metastasis in gastric cancer

doi: 10.3389/fimmu.2026.1686702

Figure Lengend Snippet: CircRERE(4-5) promotes oncogenic activity through ONECUT2 in GC cells. (A) Representative western blot of ONECUT2 protein in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. (B, C) Plate colony formation assay evaluating colony formation in AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. (D) CCK-8 assay depicting the proliferation of AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5)), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. (E, F) Transwell migration assay illustrating the migration of AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. Scale bar, 100 µm. (G, H) Wound healing assay demonstrating the migration of AGS cells under control conditions (sh-NC), after circRERE(4-5) knockdown (sh-circRERE(4-5), or following cotransfection with sh-circRERE(4-5) and ONECUT2 vector. Scale bar, 200 µm. Data are presented as the mean ± SD. P- values were calculated using a two-tailed unpaired Student’s t -test (C, F, H) or two-way ANOVA (D) ; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. See also Supplementary Figure 5 .

Article Snippet: Additionally, the overexpression vectors (GV367) for ONECUT2 were obtained from GeneChem.

Techniques: Activity Assay, Western Blot, Control, Knockdown, Cotransfection, Plasmid Preparation, Colony Assay, CCK-8 Assay, Transwell Migration Assay, Migration, Wound Healing Assay, Two Tailed Test

CircRERE(4-5) knockdown suppresses GC tumorigenesis and metastasis. (A) Tumour images of AGS cell derived xenograft (CDX) from mice receiving intratumoral injections of control ASOs or in vivo -optimized circRERE(4-5) ASOs. (B) Tumour growth trajectories in each group of mice. (C) Tumour weights in each group of mice. (D) qRT–PCR demonstrating the expression levels of circRERE(4-5) and ONECUT2 mRNA in tumours from control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups. (E, F) IHC staining illustrating the expression levels of ONECUT2 protein in tumours from control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups. Scale bar, 50 µm (left), 20 µm (right). (G, H) The dissemination of AGS cells in control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups was visualized by bioluminescence imaging using the IVIS ® Spectrum imaging system. Bioluminescent signals were captured after intraperitoneal injection of 150 mg/kg D-luciferin 10 minutes prior to imaging. (I) Lung metastasis nodules in mice receiving intravenous injections of control ASOs or in vivo -optimized circRERE(4-5) ASOs. Scale bar, 100 µm. (J) The count of lung metastasis nodules in control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups. Data are presented the as mean ± SD. P -values were calculated using a two-tailed unpaired Student’s t -test (C, D, F, H, J) or two-way ANOVA (B) ; ** P < 0.01, *** P < 0.001. See also <xref ref-type=Supplementary Figure 6 . " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Silencing of circRERE(4-5) inhibits ONECUT2-mediated tumorigenesis and metastasis in gastric cancer

doi: 10.3389/fimmu.2026.1686702

Figure Lengend Snippet: CircRERE(4-5) knockdown suppresses GC tumorigenesis and metastasis. (A) Tumour images of AGS cell derived xenograft (CDX) from mice receiving intratumoral injections of control ASOs or in vivo -optimized circRERE(4-5) ASOs. (B) Tumour growth trajectories in each group of mice. (C) Tumour weights in each group of mice. (D) qRT–PCR demonstrating the expression levels of circRERE(4-5) and ONECUT2 mRNA in tumours from control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups. (E, F) IHC staining illustrating the expression levels of ONECUT2 protein in tumours from control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups. Scale bar, 50 µm (left), 20 µm (right). (G, H) The dissemination of AGS cells in control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups was visualized by bioluminescence imaging using the IVIS ® Spectrum imaging system. Bioluminescent signals were captured after intraperitoneal injection of 150 mg/kg D-luciferin 10 minutes prior to imaging. (I) Lung metastasis nodules in mice receiving intravenous injections of control ASOs or in vivo -optimized circRERE(4-5) ASOs. Scale bar, 100 µm. (J) The count of lung metastasis nodules in control (ASO-NC) or circRERE(4-5) knockdown (ASO-circRERE(4-5)) groups. Data are presented the as mean ± SD. P -values were calculated using a two-tailed unpaired Student’s t -test (C, D, F, H, J) or two-way ANOVA (B) ; ** P < 0.01, *** P < 0.001. See also Supplementary Figure 6 .

Article Snippet: Additionally, the overexpression vectors (GV367) for ONECUT2 were obtained from GeneChem.

Techniques: Knockdown, Derivative Assay, Control, In Vivo, Quantitative RT-PCR, Expressing, Immunohistochemistry, Imaging, Injection, Two Tailed Test